跳至主要内容
临床试验/NCT04273542
NCT04273542进行中(未招募)不适用

Multicenter Large-scale Validation Study of the Interest of Broadband Spectroscopy Analysis (Femto/Attosecond by Infrared Laser) on Liquid Biopsies in Breast Cancer Screening

Centre Jean Perrin16 个研究点 分布在 1 个国家目标入组 1,100 人开始时间: 2021年5月31日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
1,100
试验地点
16
主要终点
Validation of the value of molecular profiling analysis in broadband laser spectroscopy on liquid biopsies for breast cancer screening

研究概览

简要总结

The purpose of this study is to validate the interest of broadband spectroscopy analysis (femto/attosecond by infrared laser) on liquid biopsies in breast cancer screening.

详细描述

Each patient will have one or more liquid biopsy during the follow-up according to the cohort and have a mammogram at the same time.

Biopsies will be analysed by broadband spectroscopy in order to compare the results to mammogram result.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者
是

入选标准

  • •*For all participants :
  • •Adult woman capable of giving informed consent to research participation
  • •Affiliation to the French social security system
  • •>For Control cohort:
  • •Woman participating in organised screening or benefiting from individual follow-up, eligible as such for a mammogram
  • •>For Patient cohort:
  • •woman with invasive breast cancer T0N1, T1N0-1, T2N0-1 (histologically proven) at inclusion and before any cancer treatment
  • •>For Exploratory cohort:
  • •woman carrying the BRCA1/2 mutation, followed according to standard recommendations or
  • •woman carrying the BRCA1/2 mutation suffering from in situ BC discovered on biopsy and histologically confirmed

排除标准

  • •For all participants :
  • •Refusal to participate
  • •Reluctant or unable to comply with study requirements
  • •Pregnant or breastfeeding woman
  • •History of breast cancer
  • •For Patient cohort
  • •- Patients with Stage III/IV or Bilateral Breast Cancer
  • •For Control cohort:
  • •Invasive breast cancer suspected at mammography before liquid biopsy*
  • •Mammography classified ACR3 or ACR4
  • •For Exploratory cohort:
  • •Concomitant breast cancer
  • •At inclusion visit, woman for whom an invasive breast cancer will be suspected at mammography will be include in Patient cohort after an histological proof of cancer

研究组 & 干预措施

Patient cohort

Other

In this cohort, women for who an invasive breast cancer has been diagnose will be included.

Only one liquid biopsy will be collected before any treatment.

干预措施: liquid biopsy (Other)

Exploratory cohort

Other

In this cohort, women with high risk of BRCA1/2 mutation but without invasive breast cancer.

6 liquid biopsies will be collected : each year after inclusion during 5 years.

干预措施: liquid biopsy (Other)

Control cohort

Other

In this cohort, women recruited participated to organised breast cancer screening. They must not have an invasive breast cancer.

They will have 3 liquid biopsy : the first at inclusion and then at each mammogram every two years (organised breast cancer screening).

干预措施: liquid biopsy (Other)

结局指标

主要结局

Validation of the value of molecular profiling analysis in broadband laser spectroscopy on liquid biopsies for breast cancer screening

时间窗: Comparison between the different cohorts at (T0 : inclusion) and the others visits (T1:+1year; T2: +2years; T3 : +3years; T4:+4years; T5: 5years)

To validate the value of molecular profiling analysis in broadband laser spectroscopy on liquid biopsies for invasive breast cancer screening by comparing a cohort of patients with localized invasive breast cancer (Stage I/II) to a cohort of women without invasive breast cancer from organized or individual age-matched screening.

次要结局

  • Correlating the results of high-speed laser spectroscopy analysis on liquid biopsies with mammography data (ACR 0-5)(T0: inclusion; T1:+1year; T2: +2years; T3 : +3years; T4:+4years; T5: 5years)
  • Comparison of BRCA1/2 patients molecular profiles with control and patient cohorts derived from broadband laser spectroscopy(T0: inclusion; T1:+1year; T2: +2years; T3 : +3years; T4:+4years; T5: 5years)
  • Estimate detection rate of both breast cancer screening methods (spectroscopy/mammography) for control cohort(T0 : inclusion; T2 : +2 years; T4: +4years)
  • To study the role of confounding factors in the structure of molecular profiles derived from broadband laser spectroscopy(T0: inclusion; T1:+1year; T2: +2years; T3 : +3years; T4:+4years; T5: 5years)

研究者

发起方
Centre Jean Perrin
申办方类型
Other
责任方
Sponsor

研究点 (16)

Loading locations...

相似试验